Yokoyama N, Maeda K, Tohya Y, Kawaguchi Y, Shin Y S, Ono M, Ishiguro S, Fujikawa Y, Mikami T
Department of Veterinary Microbiology, Faculty of Agriculture, University of Tokyo, Japan.
Arch Virol. 1996;141(3-4):481-94. doi: 10.1007/BF01718312.
We constructed a recombinant feline herpesvirus type 1 (FHV-1) which was deleted in a defined region (450 bp) within the thymidine kinase (TK) gene (C7301dlTK) [Yokoyama et al. (1995) J Vet Med Sci 57: 709-714]. In this report, we carried out two experiments to assess the pathogenicity and vaccine efficacy of the recombinant C7301dlTK in cats. The first experiment showed that, following multiple inoculation of the recombinant C7301dlTK by intraocular, intranasal and oral routes, the virus was sufficiently attenuated in cats, although a high titer of the virus was recovered from target organs (eye, nose, and mouth). In the second experiment, two intramuscular vaccinations with the recombinant C7301dlTK protected cats to a significant degree against subsequent challenge with the parent FHV-1 strain C7301 at 4 weeks after the last vaccination. These results demonstrate that the recombinant C7301dlTK is effective as a live attenuated vaccine with a clear genetic marker.
我们构建了一种重组猫疱疹病毒1型(FHV-1),该病毒在胸苷激酶(TK)基因的特定区域(450 bp)缺失(C7301dlTK)[横山等人(1995年)《兽医医学科学杂志》57:709 - 714]。在本报告中,我们进行了两项实验,以评估重组C7301dlTK在猫中的致病性和疫苗效力。第一项实验表明,通过眼内、鼻内和口服途径多次接种重组C7301dlTK后,尽管从靶器官(眼、鼻和口)中回收了高滴度的病毒,但该病毒在猫中充分减毒。在第二项实验中,用重组C7301dlTK进行两次肌肉注射疫苗接种,在最后一次接种后4周,能使猫在很大程度上抵御随后亲本FHV-1毒株C7301的攻击。这些结果表明,重组C7301dlTK作为一种具有明确遗传标记的减毒活疫苗是有效的。